Med School: Separating Hype from Hope in Genome Science

Genomic discoveries were supposed to transform medicine and move us to a new vision of preventive health care. But 15 years after the Human Genome Project was complete, that still hasn’t happened. Meanwhile, direct-to-consumer genetics companies are bypassing health care providers to market ancestry, disease risk, diet, exercise and even dating and wine applications directly to the public. Robert Green, one of the world’s leaders in generating the evidence-base for genomic medicine, describes what's right and what’s wrong with the genomic revolution, and how we can realize the promise of precision medicine for all.
(Underwritten by America's Biopharmaceutical Companies)

Speakers: Robert C. Green
Festival: Spotlight Health 2018

Watch and Listen: Health

Gun violence in the US is a public health epidemic. With partisan battles currently making state and federal... See more
Advances in women’s health have led to breakthroughs in breast cancer imaging, hormone therapy, and longer lives for... See more
The states shoulder a significant amount of responsibility for tackling the opioid epidemic, reversing obesity trends,... See more
The complexity of indigenous cultures is underappreciated by most modern observers, yet native people have... See more
Opioids have attracted much of the public attention given to drug abuse in recent years, but they are far from the... See more
Chronic obstructive pulmonary disease (COPD), is the third leading killer in the US, yet it rarely commands the... See more

Pages